PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
A61K 31/55, C07D 401/12

A1

(11) International Publication Number: WO 97/24124

(43) International Publication Date: 10 July 1997 (10.07.97)

(21) International Application Number: PCT/US96/20327

(22) International Filing Date: 20 December 1996 (20.12.96)

(30) Priority Data:
60/009,367 29 December 1995 (29.12.95) US

(71) Applicant *(for all designated States except US)*: SMITHKLINE BEECHAM CORPORATION [US/US]; Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: ALI, Fadia, E. [US/US]; 5 North Green Acre Drive, Cherry Hill, NJ 08003 (US). BONDINELL, William, E. [US/US]; 1512 Franklin Lane, Wayne, PA 19087 (US). KEENAN, Richard, M. [US/US]; 796 Bass Cove, Malvern, PA 19355 (US). KU, Thomas, Wen, Fu [US/US]; 1413 Southwind Way, Dresher, PA 19025 (US). MILLER, William, H. [US/US]; 333 Fell Lane, Schwenksville, PA 19473 (US). SAMANEN, James [US/US]; 145 Jug Hollow Road, Phoenixville, PA 19460 (US).

(74) Agents: McCARTHY, Mary, E. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).

(81) Designated States: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KG, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: VITRONECTIN RECEPTOR ANTAGONISTS

(57) Abstract



(I)

Compounds of formula (I) are disclosed, wherein: A is a fibrinogen antagonist template; W is a linking moiety of the form -(CHR^s)$_a$-U-(CHR^s)$_b$-V-; Q^1, Q^2, Q^3 and Q^4 are independently N or C-R^y, provided that no more than one of Q^1, Q^2, Q^3 and Q^4 is N; R' is H or C_{1-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl or Ar-C_{0-6}alkyl; R^s is H or C_{1-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl or Ar-C_{0-6}alkyl; R^k is R^s, -C(O)R^s or -C(O)OR^s R^i is H, C_{1-6}alkyl, Het-C_{0-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl, Ar-C_{0-6}alkyl, Het-C_{0-6}alkyl-U'-C_{1-6}alkyl, C_{3-7}cycloalkyl-C_{0-6}alkyl-U'-C_{1-6}alkyl or Ar-C_{0-6}alkyl-U'-C_{1-6}alkyl; R^y is H, halo, -OR^s, -SR^s, -CN, -NR^{s}R^k, -NO$_2$, -CF$_3$, CF$_3$S(O)$_r$-, -CO$_2$R^s, -COR^s or -CONR$^s_2$, or C_{1-6}alkyl optionally substituted by halo, -OR^s, -SR^s, -CN, -NR^{s}R'', -NO$_2$, -CF$_3$, R'S(O)$_3$-, -CO$_2$R^s, -COR^s or -CONR$^s_2$; U and V are absent or CO, CR$^s_2$, C(=CR$^s_2$), S(O)$_c$, O, NR^s, CR^{s}OR^s, CR^s(OR^k)CR$^s_2$, CR$^s_2$CR^s(OR^k), C(O)CR$^s_2$, CR$^s_2$C(O), CONR^i, NR^{i}CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR^s, NR^{s}C(S), S(O)$_2$NR^s, NR^{s}S(O)$_2$N=N, NR^{s}NR^s, NR^{s}CR$^s_2$, NR^{s}CR$^s_2$, CR$^s_2$O, OCR$^s_2$, CR^s=CR^s, C≡C, Ar or Het; a is 0, 1, 2 or 3; b is 0, 1 or 2; c is 0, 1 or 2; r is 0, 1 or 2; and u is 0 or 1; or pharmaceutically acceptable salts thereof, which are vitronectin receptor antagonists useful in the treatment of osteoporosis.

* (Referred to in PCT Gazette No. 41/1997, Section II)